SEC Form 4 · accession 0001562180-16-002647
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy J Barberich
Director
Period of report
Jun 15, 2016
Accepted (ET)
Jun 16, 2016 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.29 | Jun 15, 2016 | A | 12,000 | A | — | Jun 14, 2026 | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F1This option vests with respect to 100% of the shares underlying the option on June 15, 2017 subject to his continued service on Tokai's Board of Directors.